» Articles » PMID: 27008039

Use of Menopausal Hormone Therapy and Bioidentical Hormone Therapy in Australian Women 50 to 69 Years of Age: Results from a National, Cross-Sectional Study

Overview
Journal PLoS One
Date 2016 Mar 24
PMID 27008039
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Menopausal Hormone Therapy (MHT) use in Australia fell by 55% from 2001 to 2005, following the release of large-scale findings on its risks and benefits. Comprehensive national data, including information on overall prevalence of MHT use as well as information on duration of use in Australia have not been reported since the 2004-5 National Health Survey, when 11% of women aged 45+ years were estimated to be current MHT users. No national data are available on prevalence of use of "bioidentical" hormone therapy (BHT). The objective of this study was to determine recent prevalence of MHT and BHT use. A cross-sectional, national, age-stratified, population survey was conducted in 2013. Eligible women, aged 50-69 years, resident in Australia were randomly sampled in 5-year age groups from the Medicare enrolment database (Australia's universal health scheme). The response rate was 22% based on return of completed questionnaires, and analyses were restricted to 4,389 women within the specified age range. The estimated population-weighted prevalence of current use of MHT was 13% (95%CI 12-14), which was broadly similar to the previously reported national figures in 2004-5, suggesting that the use of MHT in Australia has largely stabilised over the past decade. A total of 39% and 20% of current-users with an intact uterus reported use of oestrogen-progestagen MHT and oestrogen-only MHT, respectively, whereas 77% of hysterectomised current-users used oestrogen-only MHT. Almost three-quarters of current-users [population-weighted prevalence 9% (95%CI 8-10)] had used MHT for ≥5 years. In regard to BHT, estimated population-weighted prevalence of ever use was 6% (95%CI 6-7) and 2% (95%CI 2-3) for current use. The population-weighted prevalence of MHT and BHT combined, in current users in their fifties and sixties was 15% (95%CI 14-16). These data provide a recent national "snapshot" of Australian women's use of both conventional MHT and of BHT.

Citing Articles

Menopausal symptoms and utilization of menopausal hormone therapy among women aged 40-60 years in Addis Ababa, Ethiopia: a cross-sectional study.

Asfaw T, Gebreyohannes R, Tesfaye M BMC Womens Health. 2024; 24(1):515.

PMID: 39272098 PMC: 11401244. DOI: 10.1186/s12905-024-03359-7.


Geographic Variation in Osteoporosis Treatment in Postmenopausal Women: A 15-Year Longitudinal Analysis.

Jones A, Enticott J, Ebeling P, Mishra G, Teede H, Vincent A J Endocr Soc. 2024; 8(8):bvae127.

PMID: 39035035 PMC: 11258558. DOI: 10.1210/jendso/bvae127.


Prevalence and Characteristics of Low-renin Hypertension in a Primary Care Population.

Shah S, Libianto R, Gwini S, Rusell G, Young M, Fuller P J Endocr Soc. 2024; 8(8):bvae113.

PMID: 38957654 PMC: 11215789. DOI: 10.1210/jendso/bvae113.


Sex-dimorphism in human serum endocannabinoid and n-acyl ethanolamine concentrations across the lifespan.

Hamzah K, Toms L, Kucharski N, Orr J, Turner N, Hobson P Sci Rep. 2023; 13(1):23059.

PMID: 38155287 PMC: 10754838. DOI: 10.1038/s41598-023-50426-4.


Accurate categorisation of menopausal status for research studies: a step-by-step guide and detailed algorithm considering age, self-reported menopause and factors potentially masking the occurrence of menopause.

Yap S, Vassallo A, Goldsbury D, Salagame U, Velentzis L, Banks E BMC Res Notes. 2022; 15(1):88.

PMID: 35246240 PMC: 8895593. DOI: 10.1186/s13104-022-05970-z.


References
1.
Iftikhar S, Shuster L, Johnson R, Jenkins S, Wahner-Roedler D . Use of bioidentical compounded hormones for menopausal concerns: cross-sectional survey in an academic menopause center. J Womens Health (Larchmt). 2011; 20(4):559-65. DOI: 10.1089/jwh.2009.1915. View

2.
Canfell K, Banks E, Clements M, Kang Y, Moa A, Armstrong B . Sustained lower rates of HRT prescribing and breast cancer incidence in Australia since 2003. Breast Cancer Res Treat. 2009; 117(3):671-3. DOI: 10.1007/s10549-009-0331-3. View

3.
MacLennan A, Gill T, Broadbent J, Taylor A . Continuing decline in hormone therapy use: population trends over 17 years. Climacteric. 2009; 12(2):122-30. DOI: 10.1080/13697130802666251. View

4.
Pinkerton J, Santoro N . Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women. Menopause. 2015; 22(9):926-36. PMC: 4547729. DOI: 10.1097/GME.0000000000000420. View

5.
Whelan A, Jurgens T, Trinacty M . Defining bioidentical hormones for menopause-related symptoms. Pharm Pract (Granada). 2014; 9(1):16-22. PMC: 4132968. DOI: 10.4321/s1886-36552011000100003. View